Joshua D Grill

List of Publications by Year
in descending order

66 papers	1,717 citations	279487 23 h-index	301761 39 g-index
66 all docs	66 docs citations	66 times ranked	2036 citing authors

#	Article	IF	Citations
1	Targeting Prodromal Alzheimer Disease With Avagacestat. JAMA Neurology, 2015, 72, 1324.	4.5	179
2	Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimer's Research and Therapy, 2010, 2, 34.	3.0	144
3	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimer's Research and Therapy, 2015, 7, 26.	3.0	106
4	Current therapeutic targets for the treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 711-728.	1.4	101
5	Facilitating Alzheimer Disease Research Recruitment. Alzheimer Disease and Associated Disorders, 2014, 28, 1-8.	0.6	86
6	African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 57-64.	1.8	71
7	Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. JAMA Network Open, 2021, 4, e2114364.	2.8	68
8	Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology, 2013, 80, 282-288.	1.5	58
9	Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiology of Aging, 2013, 34, 62-72.	1.5	49
10	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. JAMA Neurology, 2020, 77, 1504.	4.5	48
11	Communicating mild cognitive impairment diagnoses with and without amyloid imaging. Alzheimer's Research and Therapy, 2017, 9, 35.	3.0	46
12	Changes in regional cerebral blood flow associated with a 45â€¯day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study. Experimental Gerontology, 2018, 111, 118-121.	1.2	45
13	The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. Nature Reviews Neurology, 2021, 17, 523-524.	4.9	44
14	Constructing a Local Potential Participant Registry to Improve Alzheimerâ€™s Disease Clinical Research Recruitment. Journal of Alzheimer's Disease, 2018, 63, 1055-1063.	1.2	37
15	Why are Spousal Caregivers More Prevalent than Nonspousal Caregivers as Study Partners in AD Dementia Clinical Trials?. Alzheimer Disease and Associated Disorders, 2015, 29, 70-74.	0.6	35
16	Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. Neurobiology of Aging, 2016, 39, 147-153.	1.5	35
17	Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment. Alzheimer's and Dementia, 2013, 9, 356.	0.4	33
18	Attitudes toward clinical trials across the Alzheimerâ€™s disease spectrum. Alzheimer's Research and Therapy, 2017, 9, 81.	3.0	33

#	Article	IF	Citations
19	Patient and caregiver reactions to clinical amyloid imaging. Alzheimer's and Dementia, 2017, 13, 924-932.	0.4	30
20	Should we disclose amyloid imaging results to cognitively normal individuals?. Neurodegenerative Disease Management, 2013, 3, 43-51.	1.2	29
21	Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 15-22.	1.2	29
22	Study partners: essential collaborators in discovering treatments for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 101.	3.0	29
23	Are Patients Whose Study Partners Are Spouses More Likely to be Eligible for AlzheimerÂ's Disease Clinical Trials. Dementia and Geriatric Cognitive Disorders, 2012, 33, 334-340.	0.7	25
24	Racial and ethnic differences in older adultsâ€™ willingness to be contacted about Alzheimer's disease research participation. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12023.	1.8	25
25	Retention of Alzheimer Disease Research Participants. Alzheimer Disease and Associated Disorders, 2019, 33, 299-306.	0.6	24
26	Study partners should be required in preclinical Alzheimerâ€™s disease trials. Alzheimer's Research and Therapy, 2017, 9, 93.	3.0	22
27	Reactions to learning a â€œnot elevatedâ€•amyloid PET result in a preclinical Alzheimerâ€™s disease trial. Alzheimer's Research and Therapy, 2018, 10, 125.	3.0	20
28	A Preliminary Study of Clinical Trial Enrollment Decisions Among People With Mild Cognitive Impairment and Their Study Partners. American Journal of Geriatric Psychiatry, 2019, 27, 322-332.	0.6	20
29	Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimerâ€™s disease clinical trials. Alzheimer's Research and Therapy, 2015, 7, 39.	3.0	19
30	The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease. Contemporary Clinical Trials, 2013, 36, 256-262.	0.8	18
31	Recruiting to preclinical Alzheimer's disease clinical trials through registries. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 205-212.	1.8	17
32	Choosing Alzheimer's disease prevention clinical trial populations. Neurobiology of Aging, 2014, 35, 466-471.	1.5	15
33	Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimerâ€™s disease: study partner vs. participant accuracy. Alzheimer's Research and Therapy, 2019, 11, 85.	3.0	13
34	Study partner types and prediction of cognitive performance: implications to preclinical Alzheimerâ€™s trials. Alzheimer's Research and Therapy, 2019, 11, 92.	3.0	13
35	Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?. Alzheimer Disease and Associated Disorders, 2019, 33, 104-112.	0.6	12
36	Recruiting the Oldest-old for Clinical Research. Alzheimer Disease and Associated Disorders, 2019, 33, 160-162.	0.6	11

#	Article	IF	Citations
37	Recruitment and retention of participant and study partner dyads in two multinational Alzheimerâ€™s disease registration trials. Alzheimer's Research and Therapy, 2021, 13, 16.	3.0	11
38	A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 50.	3.0	10
39	Frequency and Impact of Informant Replacement in Alzheimer Disease Research. Alzheimer Disease and Associated Disorders, 2015, 29, 242-248.	0.6	10
40	Participantâ€“Informant Relationships Affect Quality of Life Ratings in Incipient and Clinical Alzheimer Disease. American Journal of Geriatric Psychiatry, 2017, 25, 297-307.	0.6	10
41	Attitudes toward Potential Participant Registries. Journal of Alzheimer's Disease, 2017, 56, 939-946.	1.2	9
42	Research Attitudes Questionnaire scores predict Alzheimerâ€™s disease clinical trial dropout. Clinical Trials, 2021, 18, 237-244.	0.7	9
43	Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing. Alzheimer's and Dementia, 2022, 18, 1969-1979.	0.4	8
44	Does Alzheimer Disease Pathologic Change Underlie Subjective Cognitive Complaints?. Alzheimer Disease and Associated Disorders, 2015, 29, 350-352.	0.6	5
45	Public Understanding and Opinions regarding Genetic Research on Alzheimerâ€™s Disease. Public Health Genomics, 2018, 21, 228-237.	0.6	5
46	Asian Americans and Pacific Islandersâ€™ perspectives on participating in the CARE recruitment research registry for Alzheimer's disease and related dementias, aging, and caregiving research. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12195.	1.8	5
47	Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials. Neurology, 2021, 97, 496-500.	1.5	5
48	Reasons for undergoing amyloid imaging among cognitively unimpaired older adults. Annals of Clinical and Translational Neurology, 2021, 8, 1646-1655.	1.7	5
49	Online seminars as an information source for direct-to-consumer stem cell therapy. Regenerative Medicine, 2022, 17, 81-90.	0.8	5
50	Perceptions of Research Burden and Retention Among Participants in ADRC Cohorts. Alzheimer Disease and Associated Disorders, 0, Publish Ahead of Print, .	0.6	5
51	Does Study Partner Type Impact the Rate of Alzheimer's Disease Progression?. Journal of Alzheimer's Disease, 2013, 38, 507-514.	1.2	4
52	Direct Mail Recruitment to a Potential Participant Registry. Alzheimer Disease and Associated Disorders, 2021, 35, 80-83.	0.6	4
53	Retaining Participants in Longitudinal Studies of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 87, 945-955.	1.2	4
54	On the design of early-phase Alzheimerâ€™s disease clinical trials with cerebrospinal fluid tau outcomes. Clinical Trials, 2021, 18, 714-723.	0.7	3

#	Article	IF	Citations
55	Should persons with autosomal dominant AD be included in clinical trials?. Alzheimer's Research and Therapy, 2011, 3, 18.	3.0	2
56	Consider the Source. Alzheimer Disease and Associated Disorders, 2015, 29, 364.	0.6	2
57	Youâ€™ve Got a Friend in Me: How Cognitively Unimpaired Older Adults Select a Study Partner to Participate with Them in Alzheimerâ€™s Disease Research. Journal of Alzheimer's Disease, 2022, , 1-13.	1.2	2
58	Strategies Associated with Retaining Participants in the Longitudinal National Alzheimerâ€™s Coordinating Center Uniform Data Set Study. Journal of Alzheimer's Disease, 2022, 87, 1557-1566.	1.2	2
59	Dyadic Enrollment in a Phase 3 Mild Cognitive Impairment Clinical Trial. Alzheimer Disease and Associated Disorders, 2022, Publish Ahead of Print, .	0.6	2
60	A Scoping Review of Dietary Factors Conferring Risk or Protection for Cognitive Decline in APOE Îµ4 Carriers. Journal of Nutrition, Health and Aging, 2021, 25, 1167-1178.	1.5	1
61	S3-02-04: Ethics in Alzheimer's disease prevention clinical trial design. , 2015, 11, P211-P211.		0
62	P3â€006: Racial Differences in Willingness to Enroll in Preclinical Alzheimer's Disease Clinical Trials. Alzheimer's and Dementia, 2016, 12, P819.	0.4	0
63	P4â€328: Communicating Mild Cognitive Impairment Diagnosis with and Without Amyloid Imaging: Recommendations From An Expert Workgroup. Alzheimer's and Dementia, 2016, 12, P1160.	0.4	0
64	Response to â€œAvoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosureâ€• Alzheimer's Research and Therapy, 2019, 11, 51.	3.0	0
65	Diversifying Recruitment Registries: Considering Neighborhood Health Metrics. journal of prevention of Alzheimer's disease, The, 2022, 9, 1-7.	1.5	0
66	Alzheimerâ€™s Disease Clinical Trial Study Partners. , 2022, , 333-342.		0